Terlipressin was more effective in reversing hepatorenal syndrome–acute kidney injury at 14 days.
The treatment of hepatorenal syndrome (HRS) has been focused on patients with decompensated cirrhosis. However, HRS related to acute-on-chronic liver failure (ACLF) is quite common in clinical practice, and little is known regarding the efficacy of vasoconstrictor therapy in this population.
To compare the efficacy of two vasoconstrictors, terlipressin and noradrenaline, for treatment of patients with ACLF and HRS–acute kidney injury (AKI; based on diagnostic criteria set by the International Club of Ascites), researchers randomized 120 patients to receive albumin with infusion of open-label terlipressin at 2 to 12 mg/day or noradrenaline at 0.5 to 3 mg/hour. The primary endpoint was reversal of HRS-AKI at day 14.
On intention-to-treat analys…
Reviewing Author
DisclosuresNothing to disclose
DisclosuresNothing to disclose